RANI – rani therapeutics holdings, inc. - class a (US:NASDAQ)
Stock Stats
News
Rani Therapeutics (RANI) is now covered by Lake Street Capital. They set a "buy" rating and a $9.00 price target on the stock.
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
Rani Therapeutics (RANI) had its price target lowered by Canaccord Genuity Group Inc. from $9.00 to $5.00. They now have a "buy" rating on the stock.
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth [Yahoo! Finance]
Rani Therapeutics (RANI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
Form ARS Rani Therapeutics Holdin For: Dec 31
Form DEFA14A Rani Therapeutics Holdin
Form DEF 14A Rani Therapeutics Holdin For: May 28
Form 3 Rani Therapeutics Holdin For: Mar 18 Filed by: Javadi Alireza
Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: VANGUARD GROUP INC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.